# Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept

> **NCT00581165** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 500 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00581165
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2007-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00581165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00581165, "Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00581165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*